MannKind | MNKD - Sales Revenues


MannKind reported $82.13M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
Dynavax Technologies USD 94.9M 540K Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Insmed USD 142M 34.6M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
MannKind USD 82.13M 5.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Novo Nordisk DKK 12.53B 560M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Xencor USD 21M 22.61M Sep/2025